BNCM: Delex Releases its Audited Financials and High Growth Strategy for 2026.

January 5, 2026 – Bounce Mobile Systems, Inc. (OTC: BNCM), soon to be Delex Healthcare Group, is pleased to announce that it has officially released its Independent Auditor’s Report issued on July 22, 2025, by the Company’s auditor, PwC (PricewaterhouseCoopers).

2026 Financial Reporting Timelines

In alignment with its commitment to transparency and regulatory compliance, the Company has established the following disclosure schedules:

• FY2025 Unaudited Financials: Target release by end-January 2026.
• FY2025 Audited Financial Statements: Target release by June 2026.

Following a year of robust operational performance in 2025, Delex Healthcare is positioned for accelerated growth in profitability and market share throughout 2026.

2026 Strategic Expansion Initiatives

To capitalize on emerging market opportunities, the Company is executing a multi-pillar expansion strategy:

1. Expand Retail Footprint

The Group is transitioning from its current 5-branch pilot to a nationwide scale-up via its subsidiary, MD Pharma. The Company aims to establish 80 to 100 retail pharmacy and healthcare outlets under the Med4U brand, targeting high-growth geographic corridors.

2. Expand High-Growth Business Units

i.        Diabetes Care Unit: Focused on integrated chronic disease management. This unit is anchored by a strategic partnership with Yuwell Medical, a global leader in medical devices, to provide co-branded technology and patient-care solutions. This collaboration supports the Company’s expansion into the growing diabetes care market in the Philippines, where adult diabetes prevalence is projected to rise from 4.3 million in 2023 to 5.8 million by 2045, representing a market value of approximately $756 million (₱43.2 billion).

ii.      Central Nervous System (CNS) Unit: Focused on neurology and psychiatry-related treatments, addressing rising healthcare demand in CNS disorders. The Company is pursuing a strategic partnership to expand its Central Nervous System (CNS) product portfolio, beginning with Quetiapine (Seroquel), a market-leading antipsychotic originally developed by AstraZeneca and widely prescribed for schizophrenia, bipolar disorder, and major depressive disorder.

Existing Business: This initial launch builds on an existing business valued at $2.60 million, with plans to broaden the portfolio to include additional CNS therapies such as Rivastigmine transdermal patch, Paliperidone Extended-Release prefilled syringes, and Risperidone Extended-Release Injection, among others.

Synergy: Both units will integrate seamlessly with existing pharmaceutical operations, optimizing shared sales, marketing, and distribution platforms.

Market Opportunity: The Diabetes and CNS segments represent high-growth and recurring revenues with strong long-term growth potential.

3. Expand Medical Device Portfolio

Delex is aggressively broadening its Medical Device Division to include anesthesia, critical care, and advanced diagnostic systems. By deepening institutional ties with hospitals and government entities, the Company is pivoting toward a high-margin, technology-driven ecosystem that bridges pharmaceuticals and med-tech.

4. Expand Infrastructure and Supply Chain Fortification

To support this rapid scaling, the Company will commence construction of a state-of-the-art Central Warehouse and Corporate Headquarters. This facility is designed to optimize inventory turnover, reduce logistical overhead, and provide the storage capacity required for the Group’s expanding product lines.

About Bounce Mobile Systems, Inc. (BNCM)

On July 2, 2024, Bounce Mobile Systems Inc. (BNCM) and Delex Healthcare Group Inc. (DELEX) entered into a definitive merger agreement. The Company is currently finalizing the regulatory requirements to complete its corporate name change to Delex Healthcare Group.

About Delex Healthcare Group Inc. (DELEX)

DELEX is a premier pharmaceutical leader in the Philippines, specializing in the development and distribution of critical care, anti-infectives, anesthesia, oncology, and women’s health products. DELEX currently has over 40 FDA (Philippines) approved products and supplies to over 900 hospitals, pharmacies, and clinics across the country.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of safe harbor provisions. These statements are based on current expectations and involve risks that could cause actual results to differ materially. Factors include market volatility, regulatory delays, and competitive shifts.

Investor & Media Contact

Hatadi Supaat

Chief Executive Officer

Email   : [email protected]